HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anneke Van der Walt Selected Research

Multiple Sclerosis

1/2024Transcriptomics identifies blunted immunomodulatory effects of vitamin D in people with multiple sclerosis.
1/2024Comparative efficacy of ofatumumab versus oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons.
1/2024Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies.
8/2023The impact of menopause on multiple sclerosis.
1/2023Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies.
11/2022Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.
10/2022Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
11/2021Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
1/2021Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
3/2011Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Anneke Van der Walt Research Topics

Disease

11Multiple Sclerosis
01/2024 - 04/2010
2Relapsing-Remitting Multiple Sclerosis
10/2022 - 11/2021
1Disease Progression
08/2023
1Neoplasms (Cancer)
01/2023
1COVID-19
11/2022
1Tremor (Tremors)
02/2022
1Neuromyelitis Optica (Devic's Disease)
01/2022
1Stillbirth
12/2020
1Spontaneous Abortion (Miscarriage)
12/2020
1Atrophy
03/2011
1Genetic Predisposition to Disease (Genetic Predisposition)
04/2010

Drug/Important Bio-Agent (IBA)

4Natalizumab (Tysabri)FDA Link
01/2024 - 01/2021
2Fingolimod Hydrochloride (FTY720)FDA Link
11/2021 - 01/2021
2HLA-DR15 antigenIBA
03/2011 - 04/2010
1Vitamin DFDA LinkGeneric
01/2024
1ofatumumabFDA Link
01/2024
1Monoclonal AntibodiesIBA
01/2024
1Gonadal Steroid Hormones (Sex Hormones)IBA
08/2023
1Glatiramer Acetate (Copaxone)FDA Link
11/2022
1Rituximab (Mabthera)FDA Link
11/2022
1ocrelizumabIBA
11/2022
1Type A Botulinum Toxins (Botox)FDA Link
02/2022
1Myelin-Oligodendrocyte GlycoproteinIBA
01/2022
1Dimethyl FumarateIBA
01/2021
1HLA-DRB1 Chains (HLA DRB1)IBA
03/2011

Therapy/Procedure

5Therapeutics
01/2024 - 10/2022
1Induced Abortion (Induced Abortions)
12/2020